{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:07:11Z","timestamp":1793210831563,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017694","name":"Hermann and Lilly Schilling Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB CRC-TR-128"],"award-info":[{"award-number":["SFB CRC-TR-128"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB CRC-1292"],"award-info":[{"award-number":["SFB CRC-1292"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1080"],"award-info":[{"award-number":["SFB 1080"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["221828878"],"award-info":[{"award-number":["221828878"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["213904703"],"award-info":[{"award-number":["213904703"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["490846870"],"award-info":[{"award-number":["490846870"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["318346496"],"award-info":[{"award-number":["318346496"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neurot.2026.e00914","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:02:23Z","timestamp":1777593743000},"page":"e00914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment approaches to patients with multiple sclerosis and coexisting psoriasis \u2013 A longitudinal multicenter observational cohort study"],"prefix":"10.1016","volume":"23","author":[{"given":"Tobias","family":"Brummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"R\u00e4uber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice G.","family":"Willison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Schraad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Protopapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Boeckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Zipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinzenz","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e00914_bib1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.26672","article-title":"Shared genetic risk factors for multiple sclerosis\/psoriasis suggest involvement of Interleukin-17 and janus kinase-signal transducers and activators of transcription signaling","volume":"94","author":"Patrick","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e00914_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.conb.2022.102588","article-title":"T cell-neuron interaction in inflammatory and progressive multiple sclerosis biology","volume":"75","author":"Brummer","year":"2022","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.neurot.2026.e00914_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.neurot.2026.e00914_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40257-018-0399-9","article-title":"Association of multiple sclerosis with psoriasis: a systematic review and meta-analysis of observational studies","volume":"20","author":"Liu","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211035542","article-title":"Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders","volume":"14","author":"Brummer","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2026.e00914_bib6","article-title":"Treatment options for the comorbidity of multiple sclerosis with other chronic inflammatory diseases","author":"Bittner","year":"2025","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.neurot.2026.e00914_bib7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1684\/ejd.2024.4772","article-title":"Psoriasis induced at the injection sites of interferon beta in a patient with multiple sclerosis","volume":"34","author":"Hsieh","year":"2024","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib8","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.jid.2016.06.608","article-title":"Therapeutic elimination of the type 1 interferon receptor for treating psoriatic skin inflammation","volume":"136","author":"Gui","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00296-025-05902-7","article-title":"Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis\/multiple Sclerosis-like syndrome: a systematic review","volume":"45","author":"Chaitidis","year":"2025","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.neurot.2026.e00914_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00914_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdova","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2026.e00914_bib12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e00914_bib13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/13524585241260564","article-title":"Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis","volume":"30","author":"Kolsche","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2026.e00914_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.17846","article-title":"Exacerbation of psoriasis during treatment with ofatumumab for multiple sclerosis","author":"Watabe","year":"2025","journal-title":"J Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib15","first-page":"e322","article-title":"Psoriasis caused by ocrelizumab in two persons with primary progressive multiple sclerosis","volume":"61","author":"Jakob","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib16","first-page":"459","article-title":"Palmoplantar pustular psoriasis induced by ocrelizumab in a patient affected by multiple sclerosis","volume":"157","author":"Lappi","year":"2022","journal-title":"Ital J Dermatol Venerol"},{"key":"10.1016\/j.neurot.2026.e00914_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103832","article-title":"Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis","volume":"63","author":"Porwal","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e00914_bib18","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1007\/s10072-024-07616-3","article-title":"Clinical implications for the association of psoriasis and multiple sclerosis: an observational study","volume":"45","author":"Miele","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurot.2026.e00914_bib19","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"Muller","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2026.e00914_bib20","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2026.e00914_bib21","article-title":"Early comorbidities and diagnostic challenges in people with multiple sclerosis with possible impact on disease management","volume":"11","author":"Makarov","year":"2025","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.neurot.2026.e00914_bib22","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00296-021-04995-0","article-title":"Demyelinating disease (multiple sclerosis) in a patient with psoriatic arthritis treated with adalimumab: a case-based review","volume":"41","author":"Baresic","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.neurot.2026.e00914_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.03.004","article-title":"Tumor necrosis factor alpha (TNF-alpha), anti-TNF-alpha and demyelination revisited: an ongoing story","volume":"234","author":"Caminero","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurot.2026.e00914_bib24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2249.2011.04484.x","article-title":"Role of tumour necrosis factor (TNF)-alpha and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis","volume":"166","author":"Caminero","year":"2011","journal-title":"Clin Exp Immunol"},{"issue":"7412","key":"10.1016\/j.neurot.2026.e00914_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature11307","article-title":"TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis","volume":"488","author":"Gregory","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2026.e00914_bib26","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1084\/jem.20100977","article-title":"Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells","volume":"208","author":"Ghoreschi","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurot.2026.e00914_bib27","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.neurot.2026.e00914_bib28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/ced.12326","article-title":"Fumaric acid esters in psoriasis and multiple sclerosis","volume":"39","author":"Zecca","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jdermsci.2017.11.003","article-title":"Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis","volume":"89","author":"Krause","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.neurot.2026.e00914_bib30","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2026.e00914_bib31","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1111\/1346-8138.16802","article-title":"Generalized pustular psoriasis occurring in a patient with multiple sclerosis during treatment with fingolimod","volume":"50","author":"Ikumi","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib32","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.neurot.2026.e00914_bib33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/ced.15100","article-title":"Pustular psoriasis following treatment for multiple sclerosis","volume":"47","author":"Couper","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib34","article-title":"Teriflunomide-induced palmoplantar pustular psoriasis: case report and review of the literature","volume":"15","author":"Demirel Ozbek","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.neurot.2026.e00914_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26195","article-title":"Simultaneous onset of Crohn's disease and psoriasis in a multiple sclerosis patient treated with teriflunomide: a novel case report highlighting potential autoimmune interactions","volume":"10","author":"Ghiasian","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.neurot.2026.e00914_bib36","doi-asserted-by":"crossref","DOI":"10.5070\/D330464111","article-title":"Teriflunomide-related development of inverse psoriasis and worsening of pre-existing plaque psoriasis","volume":"30","author":"Mueller","year":"2024","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.neurot.2026.e00914_bib37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.msard.2018.11.020","article-title":"Palmar pustular psoriasis associated with teriflunomide treatment","volume":"27","author":"Negrotto","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e00914_bib38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/15569527.2025.2496638","article-title":"Therapeutic effect of systemic use of glatiramer acetate in imiquimod-induced mouse psoriasis model","volume":"44","author":"Demiran","year":"2025","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.neurot.2026.e00914_bib39","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/1346-8138.14619","article-title":"Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient","volume":"46","author":"Assefa","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2217\/imt-2021-0128","article-title":"Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review","volume":"14","author":"Eksin","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.neurot.2026.e00914_bib41","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1111\/jdv.16035","article-title":"Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report","volume":"34","author":"Venturini","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.neurot.2026.e00914_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13943","article-title":"Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis","volume":"33","author":"Di Tullio","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.neurot.2026.e00914_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.msard.2019.03.009","article-title":"A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions","author":"Diebold","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e00914_bib44","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1111\/ijd.14902","article-title":"Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?","volume":"59","author":"Megna","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib45","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1111\/ajd.13983","article-title":"A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab","volume":"64","author":"Megna","year":"2023","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.neurot.2026.e00914_bib46","first-page":"550","article-title":"Concomitant treatment of secukinumab and ofatumumab in a psoriasis patient with multiple sclerosis","volume":"160","author":"Lucagnano","year":"2025","journal-title":"Ital J Dermatol Venerol"},{"key":"10.1016\/j.neurot.2026.e00914_bib47","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/13524585241232277","article-title":"Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: case report and literature review","volume":"30","author":"Emma","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2026.e00914_bib48","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1007\/s00415-012-6713-1","article-title":"Psoriasis during natalizumab treatment for multiple sclerosis","volume":"259","author":"Millan-Pascual","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2026.e00914_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10072-017-3112-5","article-title":"Arthritic psoriasis during natalizumab treatment: a case report and review of the literature","volume":"39","author":"Vacchiano","year":"2018","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurot.2026.e00914_bib50","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3389\/fneur.2018.01071","article-title":"Real-world lab data in natalizumab treated multiple sclerosis patients up to 6 years long-term follow up","volume":"9","author":"Kaufmann","year":"2018","journal-title":"Front Neurol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792600084X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792600084X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:43:14Z","timestamp":1783057394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792600084X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S187874792600084X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00914","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment approaches to patients with multiple sclerosis and coexisting psoriasis \u2013 A longitudinal multicenter observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00914"}}